Page 75 - CJO_F18

RAPPORT DE CAS

RÉFÉRENCES
1. Boughton B. Update on polypoidal choroidal vasculopathy. Édito- 6. Kuo JZ, Wong TY, Ong FS. Genetic risk, ethnic variations and
rial. EyeNet Déc. 2012 : 35-7. pharmacogenetic biomarkers in age-related macular degeneration
2. Honda, S., Matsumiya, W., Negi, A. Polypoidal choroidal vasculopa- and polypoidal choroidal vasculopathy. Expert Rev Ophthalmol 2013
thy : clinical features and genetic predisposition. Ophthalmologica 1;8(2) : 127-40.
2014; 231:59-74. 7. Tan CS, Ngo WK, Lim LW, Lim TH. A novel classification of the vas-
3. Oishi A, Kojima H, Mandai M, et coll. Comparison of the effect of cular patterns of polypoidal choroidal vasculopathy and its relation
ranibizumab and verteporfin for polypoidal choroidal vasculopa- to clinical outcomes. Br J Ophthalmol 2014; 0:1-6.
thy : 12-month LAPTOP Study Results. Am J Ophthalmol 2013; 156 : 8. Ijiri, S., Sugiyama, K. « Short-term efficacy of intravitreal aflibercept
644-51. for patients with treatment-naïve polypoidal choroidal vasculopa-
4. Koh A, Lee WK, Chen LJ et coll. EVEREST study : efficacy and thy ». Graefes Arch Clin Exp Ophthalmol 2015 Mar; 253(3):351-7.
safety of verteporfin photodynamic therapy in combination with 9. Oishi, A., Miyamoto, N., Mandai, M., et coll. LAPTOP Study : A
ranibizumab or alone versus ranibizumab monotherapy in patients 24-month trial of verteporfin versus ranibizumab for polypoidal
with symptomatic macular polypoidal choroidal vasculopathy. choroidal vasculopathy. Ophthalmology, mai 2014; 121(5):1151-2.
Retina, 2012; 32:1453-64.
5. Hata, M., Tsujikawa, A., Miyake, M., et coll. Two-year visual out-
come of polypoidal choroidal vasculopathy treated with photody-
namic therapy combined with intravitreal injections of ranibizum-
ab. Graefes Arch Clin Exp Ophthalmol, février 2015; 253(2):189-97.

CANADIAN JOURNAL of OPTOMETRY | REVUE CANADIENNE D’OPTOMÉTRIE VOL. 80 NO. 3 75

38668_CJO_F18_ONLINE_ONLY_ARTICLES August 13, 2018 12:32 PM APPROVAL: ___________________ DATE: ___________________